Markets:

Overview

News

Currencies

International

Treasuries

Fennec Pharmaceuticals Inc. - Common Stock (NQ:FENC)

7.800 +0.280 (+3.72%)

Streaming Delayed Price Updated: 12:38 PM EDT, Mar 16, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Fennec Pharmaceuticals Inc. - Common Stock

< Previous 1 2 3 Next >

Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Fennec Pharmaceuticals Inc. (FENC) Investors

February 11, 2022

From Kirby McInerney LLP

Via Business Wire

Shareholder Alert: Robbins LLP Informs Investors that Fennec Pharmaceuticals Inc. (FENC) is Being Sued for Misleading Shareholders

February 11, 2022

From Robbins LLP

Via Business Wire

The Law Offices of Frank R. Cruz Announces Investigation of Fennec Pharmaceuticals Inc. (FENC) on Behalf of Investors

February 10, 2022

From The Law Offices of Frank R. Cruz

Via Business Wire

Why Fennec Pharmaceuticals's Stock is Trading Higher Today ↗

April 21, 2021

Fennec Pharmaceuticals's Stock Price And Volume Action Fennec Pharmaceuticals's (NASDAQ:

Via Benzinga

EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Fennec Pharmaceuticals Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – FENC

February 10, 2022

From The Rosen Law Firm, P.A.

Via Business Wire

Bronstein, Gewirtz & Grossman, LLC Notifies Fennec Pharmaceuticals Inc. (FENC) Investors of Investigation

February 10, 2022

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

Fennec Pharmaceuticals Inc. (NASDAQ: FENC) Investor Notice: Investigation over Possible Violations of Securities Laws ↗

December 16, 2021

San Diego, CA -- (SBWIRE) -- 12/16/2021 -- An investigation for investors in Fennec Pharmaceuticals Inc. (NASDAQ: FENC) shares over potential securities laws violations by Fennec Pharmaceuticals Inc....

Via SBWire

50 Biggest Movers From Yesterday ↗

November 30, 2021

Gainers Krystal Biotech, Inc. (NASDAQ: KRYS) shares surged 121.7% to close at $88.24 on Monday after the company announced positive topline results from the GEM-3 Phase 3 trial...

Via Benzinga

Mid-Afternoon Market Update: Dow Jumps 300 Points; Krystal Biotech Shares Spike Higher ↗

November 29, 2021

Toward the end of trading Monday, the Dow traded up 0.87% to 35,204.42 while the NASDAQ climbed 1.96% to 15,795.08. The S&P also rose, gaining 1.55% to 4,665.67. The U.S. has...

Via Benzinga

Topics Stocks

Stocks Rise as "Fear Gauge" Cools Off ↗

November 29, 2021

The Dow Jones Industrial Average and Nasdaq Composite are both up triple digits midday, paring some of their losses from Friday's massive selloff.

Via Talk Markets

Topics Stocks

Mid-Day Market Update: Crude Oil Rises 4%; Fennec Pharmaceuticals Shares Slide ↗

November 29, 2021

Midway through trading Monday, the Dow traded up 0.30% to 35,005.10 while the NASDAQ climbed 1.39% to 15,707.48. The S&P also rose, gaining 0.97% to 4,639.11. The U.S. has the...

Via Benzinga

Topics Stocks

33 Stocks Moving In Monday's Mid-Day Session ↗

November 29, 2021

Gainers Krystal Biotech, Inc. (NASDAQ: KRYS) shares jumped 116.4% to $86.13 after the company announced positive topline results from the GEM-3 Phase 3 trial of investigational...

Via Benzinga

Mid-Morning Market Update: Markets Open Higher; Li Auto Sales Top Views ↗

November 29, 2021

Following the market opening Monday, the Dow traded up 0.22% to 34,977.01 while the NASDAQ climbed 1.53% to 15,727.94. The S&P also rose, gaining 0.92% to 4,637.03. The U.S....

Via Benzinga

Topics Stocks

Fennec Pharma Stock Plunges On Expected FDA CRL For Pedmark For Chemo-Induced Hearing Issues ↗

November 29, 2021

Fennec Pharmaceuticals Inc (NASDAQ: FENC) said it expects to receive a Complete Response Letter (CRL) from the FDA regarding its marketing application for Pedmark...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗

November 29, 2021

I hope you got your rest out over the holiday weekend because we're starting off Monday with the biggest pre-market stock movers!

Via InvestorPlace

The Week Ahead In Biotech (Nov. 21-Nov. 27): FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week ↗

November 21, 2021

Biotech stocks showed a lack of direction in the week ending Nov. 19 before finishing modestly higher. Stocks did not have much meaningful catalysts to react to amid the winding down of the reporting...

Via Talk Markets

The Week Ahead In Biotech (Nov. 21-Nov. 27): Takeda, Aadi, Fennec FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week ↗

November 21, 2021

Biotech stocks showed a lack of direction in the week ending Nov. 19 before finishing modestly higher. Stocks did not have much meaningful catalysts to react to amid the...

Via Benzinga

The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance ↗

November 10, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus MorphoSys COO To Leave To Pursue Other Opportunities MorphoSys AG (NASDAQ:...

Via Benzinga

Attention Biotech Investors: Mark Your Calendar For November PDUFA Dates ↗

November 02, 2021

The loaded Prescription Drug User Fee Act (PDUFA) calendar for October produced mixed outcomes. PDUFA dates are key binary events for biotech stocks that can move the needle in a...

Via Benzinga

The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug ↗

September 29, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks...

Via Benzinga

The Daily Biotech Pulse: Sanofi, Translate Bio Start Early Stage Seasonal Flu Vaccine Study, Dr. Reddy's Launches Generic Vascepa, Halozyme Strikes Licensing Deal ↗

June 22, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 21) Agios Pharmaceuticals, Inc...

Via Benzinga

Fennec Pharma Stock Is Trading Higher As Pedmark Is Under FDA Review For Chemo-Induced Toxicity ↗

June 22, 2021

The FDA has accepted for review Fennec Pharmaceuticals Inc's (NASDAQ: FENC) resubmitted marketing application seeking approval for Pedmark (formulated sodium...

Via Benzinga

Fennec Pharma Refiles Pedmark US Application For Cisplatin-Induced Ototoxicity In Pediatric Patients ↗

May 28, 2021

Fennec Pharmaceuticals Inc (NASDAQ: FENC) has resubmitted its marketing application to the FDA seeking approval for Pedmark (formulated sodium thiosulfate) for the...

Via Benzinga

The Daily Biotech Pulse: Biohaven, Bristol-Myers Squibb Snag FDA Approvals, Iterum UTI Drug Review On Track, Centessa Pharmaceuticals Debuts On Nasdaq ↗

May 28, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 27) BioCryst Pharmaceuticals,...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 21, 2021 ↗

April 21, 2021

Upgrades For Cerecor Inc (NASDAQ:CERC), Maxim Group upgraded the previous rating of Hold to Buy. In the fourth quarter, Cerecor showed an EPS of $0.19, compared to $0.10...

Via Benzinga

51 Biggest Movers From Yesterday ↗

April 07, 2021

Gainers UTime Limited (NASDAQ: UTME) shares jumped 875% to close at $39.00 on Tuesday after the company priced its IPO at $4 per share. Romeo Power, Inc. (NYSE: RMO) climbed 59.6...

Via Benzinga

Topics Initial Public Offering

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.